Search academic texts

Information × Registration Number 0212U004403, 0110U002251 , R & D reports Title Investigating significance of a clinical manifestations, morfological and biochemical features of the malignant cells for diagnostics, course prognosis and treatment results optimization in hairy cell leukemia popup.stage_title Head Loginsky Volodymyr Eustakhovych, Доктор медичних наук Registration Date 09-02-2012 Organization State Institution Institute of Blood Pathology and Transfusion Medicine of National Academy of Medicfl Sciences of Ukraine popup.description2 Treatment efficacy as well as its direct and long-term results was analyzed for 83 patients with hairy-cell leukemia (HCL). There were 4 groups of patients created according to the treatment schemes applied. Indications for application of different treatment options for HCL were determined. Indications for treatment initiation in patients with HCL are based on criteria for disease progression. 2-CdA is recognized as a first-line treatment option which results in achievement of complete response in 83.3% and partial response - in 5.5% of HCL patients. Disease relapse was revealed in 36,1% of patients after one cycle of the 2-CdA. The 5-year event-free survival (EFS) was reached in 58% of patients whereas 10-year EFS was detected in 42% of patients who received this treatment. Therapy with 2-CdA may cause deep myelosuppression in treated subjects potentially resulting in dangerous infections. New optimized treatment method for pancytopenic patients was proposed on the basis of two-stage treatment scheme (IFN?+2-CdA), which enables achieving maximum efficacy with minimal adverse consequences of the therapy. Treatment with IFN? is recommended for the elderly patients; subjects resistant to 2-CdA; patients relapsing after previous 2-CdA treatment as well as for the splenectomized subjects. Splenectomy is suggested as a first-line option for HCL patients with significant splenomegaly and profound cytopenia. Median event-free survival for HCL patients after splenectomy is 52 months; both 5-year and 10-year EFS were achieved in 45%, and 20-year survival - in 35% of the patients. Product Description popup.authors Євстахевич Ю.Л. Барілка В.А. Виговська Я.І. Зотова О.В. Красівська В.В. Лбедь Г.Б. Логінський В. Є. Лук'янова А.С. Мазурок А.А. Пеленьо Н.В. Примак С.В. Римар М.М. Шалай О.О. Ясниський З.І. popup.nrat_date 2020-04-02 Close